This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Novartis revealed today that it may consider divesting its genericmedicines subsidiary Sandoz – amongst other options – which would further narrow its focus to innovative medicines.
“Now more than ever, it is our responsibility as a sector to ensure affordable access to healthcare and enable the future longevity of medicine development and supply.”. The genericsmedicines sector can, too, play a substantial part in discovering new areas for licensed products to be used in. Delivery of essential medicines.
The strategy to build in cancer dates back to 2015, and has since gathered momentum with the purchase of the oncology businesses of Shire and Agios Pharma in 2018 and 2020, for $2.4 billion and $1.8 billion respectively, as well as smaller deals such as its takeover of Danish antibody specialist Symphogen.
The report analyses selected companies of varying sizes that manufacture and market antibiotics – including research-based pharma companies, genericmedicine manufacturers and business-to-business providers. Despite progress, significant gaps remain.
Koye sells genericmedicines, including COPD therapies such as Spirodin (doxofylline) and Spirodin-Ax (doxofylline and ambroxol), used to reduce open the airways and reduce coughing in patients with the respiratory condition.
It looks like Astellas has been unsuccessful in its attempt to block Pfizer’s genericmedicines unit Hospira from launching a copycat version of big-selling pharmacologic stress agent Lexiscan in the US.
In a bid to resolve both physical and financial restrictions inhibiting equitable access to quality medicines, the Jan Aushadhi scheme was launched in 2008 and envisaged the setting up of dedicated Janaushadhi Kendras to provide quality genericmedicines at capped prices for the general public.
Astellas has won a reprieve in its attempt to stop Pfizer’s genericmedicines unit Hospira launching a copycat version of its pharmacologic stress agent Lexiscan in the US – but only for a couple of weeks.
The FDA’s 505(b)(2) pathway and the European Medicines Agency’s (EMA) Hybrid Pathway offer routes for drug developers to rely on previously submitted clinical data, cutting down approval times significantly. As the world’s largest manufacturer of genericmedicines, India has vast potential to utilise repurposed drugs.
With this extensive system in place, patients can trust that medicines with the same name will be consistent in quality no matter who manufactures it or where in the world it is made. Since manufacturers know the precise quality specifications, standards help make the approval process for genericmedicines more efficient.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content